Details of the Drug

General Information of Drug (ID: DM9QF65)

Drug Name
GR-MD-02
Synonyms Belapectin
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Phase 2 [1]
Melanoma 2C30 Phase 2 [2]
Plaque psoriasis EA90.0 Phase 2 [3]
Non-alcoholic steatohepatitis DB92.1 Phase 1 [4]
Drug Type
Protein
Cross-matching ID
UNII
K7ODU55HT6
DrugBank ID
DB15125
TTD ID
D06BKH
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Galectin-3 (LGALS3) TTFPQV7 LEG3_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health.
5 Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.